Johnson & Johnson stock: New Impella evidence ahead of TCT

Published on 10/29/2026 at 17:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock gets a new MedTech data point ahead of the TCT conference. The company will present Impella research in San Diego.

Neue Impella-Daten im Anlegerfokus

Johnson & Johnson stellt bei TCT klinische Daten aus Herzmedizin und Hochrisiko-Interventionen vor.
Die Mitteilung verweist auf mehr als zwei Jahrzehnte klinischer Evidenz und laufende Studien.
Der aktuelle Euro-Kurs liegt über dem im jüngsten eigenen Vorbericht gelesenen Wert.

Johnson & Johnson, US4781601046, Illustration mit AI erstellt.

Johnson & Johnson announced on October 29, 2026, that a record 26 presentations on Impella heart pumps will be presented at the Transcatheter Cardiovascular Therapeutics conference in San Diego from October 31 to November 3. The details come from the company's Johnson & Johnson press release.

What the new evidence covers

Johnson & Johnson MedTech said the programme includes research in high-risk percutaneous coronary intervention, cardiogenic shock, myocardial recovery, renal perfusion, physiologic risk and next-generation technology. The release also describes a health-economic model comparing Impella with an intra-aortic balloon pump in heart-failure patients undergoing high-risk intervention.

The company said its Impella evidence base spans more than two decades, including randomized trials, prospective studies, registries and real-world clinical practice. It also said more than 50,000 Impella patients have been studied and more than 450,000 patients worldwide have been treated with the devices. These figures describe the company's disclosed evidence base and treatment history, not a new clinical outcome from the October 29 announcement.

Course comparison and investor context

At Lang & Schwarz, the valid euro quote was EUR 246.65 on October 29, 2026, at 16:31:29 Berlin time. That was 2.47 percent above the EUR 240.70 quote recorded at 07:36 on October 28, 2026, in the most recent own report. Separately, the quote was 0.76 percent above the EUR 244.80 Xetra close from October 28; the Xetra reference was checked against Bloomberg's Xetra quote page. The different comparisons should not be read as proof that the share-price movement was caused by the new release.

Investors can use the conference programme as an additional information point for the MedTech pipeline, while the disclosed data do not remove execution, regulatory and commercial risks. The company operates through Innovative Medicine and MedTech, so the presentation programme relates to one part of its broader healthcare portfolio.